Maeil Dairies, Daewoong Pharma bid for FND Net Sale of nutritional supplement maker draws strong interest from strategic buyers
Translated by Ryu Ho-joung 공개 2021-05-17 07:54:35
이 기사는 2021년 05월 17일 07:44 thebell 에 표출된 기사입니다.
Maeil Dairies and Daewoong Pharma have submitted indicative offers for FND Net, heating up the bidding war for the nutritional supplement maker owned by Unison Capital.Apart from the two companies, many other firms in the same industry or industries related to the nutritional supplement sector have participated in the bidding for the private equity firm’s 75% stake in FND Net, sources said.
Unison Capital and Samsung Securities, which is managing the sale process, are expected to shortlist bidders in the coming week. Unison Capital is reportedly seeking a valuation of 200 billion won ($177 million) for its stake in FND Net.
Maeil Dairies is South Korea’s largest dairy producer by revenue, reposting 1.46 trillion won in revenue for the 12 months through December 2020. Its interest in acquiring FND Net is seen as part of a drive to diversify away from dairy products and transform itself into a food conglomerate.
Maeil Dairies are in a good liquidity position, with cash and cash equivalents of 118.4 billion won at the end of 2020. The company also raised 200 billion won from a bond sale last month and said some 40 billion won of the proceeds would be used to bolster its investment in nutritional supplement products.
Daewoong Pharma is also looking to expand its nutritional supplement business by acquiring FND Net, whose sales network across hospitals could create big synergies with the pharmaceutical firm. It is a latecomer to the market, launching new products in this category in April last year.
Daewoong Pharma had roughly 70 billion won in cash and cash equivalents on hand at the end of 2020, and total liquidity, including cash held by its parent company, is estimated to be about 100 billion won.
Founded in 2004, FND Net is one of the oldest nutritional supplement makers in the country. FND Net has differentiated its business model by focusing on building distribution channels through partnerships with hospitals and pharmacies. The company supplies its products through the network of more than 3000 hospitals and 4000 pharmacies, with 120 exclusive in-shop stores in large hospitals.
FND Net’s revenue has continued to grow in the past three years, from 47.6 billion won in 2018 to 61.9 billion won in 2020. Especially, revenue rose by 17.5% last year despite the impact of the Covid-19 pandemic.
FND Net has also seen its bottom line increase in the same period, from 6.7 billion won in 2018 to 7 billion won in 2020. The company’s earnings before interest, taxes, depreciation and amortization margin, a metric often used as a proxy for cash flow, were 10.2 billion won. (Reporting by Si-eun Park)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 하이브처럼 어도어 기업가치 평가해보니 '4400억'
- [Board Index/BSM분석]'정의선·일론 머스크·메리 바라'의 보유 역량 차이는
- [빅딜 그 이후]통합 셀트리온, 확대된 차입여력…조달 다변화 시동
- [레버리지&커버리지 분석]실적 부진 애경케미칼, 늘어난 단기차입 부담
- [Board Index/카카오]배당수익률 시장평균 웃도는 계열사 'SM엔터' 유일
- [Financial Index/HMM]주요 항목으로 자리 잡은 금융자산 9.2조
- [CFO는 지금]김남선 CFO, '스노우' 이사회서 빠졌다
- [조달전략 분석]상업운전 앞둔 아이지이, 차입금 상환도 임박
- [Board Index/BSM분석]카카오뱅크, 미국 최대 인뱅 찰스슈왑과 비교해보니
- '복수 FI 참여' SK의 마산그룹 투자, 풋옵션 만기 연장 가닥